News about Global Pharma

TekniPlex Healthcare Emphasizes Two EU-Based Capacity and Capabilities Expansions at Pharmapack Europe

At Stand E97 , the company will highlight its efforts to meet growing demand for sophisticated vials, bellow bottles and cleanroom-produced multilayer blown films, and also showcase products from its existing portfolio of healthcare packaging solutions.

Global Pharma | 24/12/2024 | By Manvi |  416

Ellipses Introduces Pioneering Clinical Trial Programme in Middle East

The trial will focus on Ellipses' next generation selective RET inhibitor (SRI), EP0031/A400, a potential treatment of RET-altered tumours, most prevalent in non-small cell lung cancer and thyroid cancer.

Global Pharma | 24/12/2024 | By Aishwarya |  280

PTC Therapeutics Submits NDA for Vatiquinone to FDA

The vatiquinone NDA is based on data from the placebo-controlled MOVE-FA study as well as results from two long-term studies including pediatric and adult FA patients.

Global Pharma | 24/12/2024 | By Aishwarya |  383

OBI Pharma Partners with GlyTech to Promote GlycOBI Enabling Technologies Outreach in Japan

Under the terms of the Material Transfer Agreement, OBI will transfer some of its cutting-edge materials to GlyTech for research in advancing the efficient production of glycans for ADCs.

Global Pharma | 24/12/2024 | By Aishwarya |  542

Neuraxpharm and Pharmathen to Co-Develop Long-Acting Injectable Therapies

Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm.

Global Pharma | 23/12/2024 | By Aishwarya |  566

Valneva Signs Agreement with Serum Institute of India for its Single Shot Chikungunya Vaccine

The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the framework of the USD 41.3 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union.

Global Pharma | 23/12/2024 | By Manvi |  717

HKBU's Aptamer for Rare Bone Disease Receives Orphan Drug and Rare Pediatric Disease Designations by FDA

The aptamer, originally developed to treat osteogenesis imperfecta, has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the US Food and Drug Administration (FDA).

Global Pharma | 23/12/2024 | By Manvi |  343

Photys Therapeutics and with Novo Nordisk to Develop Induced Proximity PHICS Technology

Under the terms of the agreement, Photys is eligible to receive up to USD 186 million in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales.

Global Pharma | 23/12/2024 | By Aishwarya |  725

CuraTeQ Biologics Secures UK MHRA Approval for Bevqolva

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.

Global Pharma | 23/12/2024 | By Aishwarya |  731

Verismo Therapeutics Completes Merger to Accelerate Clinical Development

The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo's and HLB Group's collective mission to advance its innovative KIR-CAR platform for patients worldwide.

Global Pharma | 21/12/2024 | By Aishwarya |  875